Deep TMS - BRAINSWAY - H Coil

Deep TMS (Deep Transcranial Magnetic Stimulator) BRAINSWAY
  • ANTIDEPRESANTLAR HASTALARINIZIN SONUÇLARINI DÜZELTMEYE YARAMADI MI?
  • Majör depresif bozukluk geleneksel olarak antidepresanlarla tedavi edilmiştir. Bununla birlikte, araştırmalar, anti-depresanların birçok hasta için tatmin edici sonuçlar elde edemediğini göstermektedir.
  • The patented breakthrough technology of Brainsway* unfolds a new dawn in depression treatment. The company offers a clinically-proven solution for various categories of depression patients, ranging from mild to severe depression cases, who failed to achieve sufficient outcomes from existing treatments in the current episode.
  • The treatment performs deep non-invasive brain stimulation using directed electromagnetic fields, generating significant improvement in the depressive symptoms.
  • Brainsway`s technology is based on patents filed by the U.S. National Institutes of Health (NIH) and the company. The treatment has been enthusiastically embraced by the international academic community, with over 60 clinical trials in leading institutions worldwide, for psychiatric and neurological indications.
  • EFFECTIVE TREATMENT
  • Brainsway Deep TMS has many advantages over traditional depression treatments.
  • The efficacy of antidepressants decreases with the number of failed medication trials1, and they also entail systemic side effects2 which lead many patients to neglect their medication regime. Other alternatives, such as Electroconvulsive Therapy (ECT), require anesthesia and may entail significant risks and side effects.
  • Therefore, in many cases, depression patients have been virtually trapped in their condition with limited solutions.
  • Brainsway`s novel Deep TMS (Deep Transcranial Magnetic Stimulation) technology holds a variety of benefits for depression patients. In addition to its noninvasive stimulation of deep brain regions and efficacy, the treatment involves no hospitalization, typically requiring only brief 20-minute daily sessions over a period of 4-6 weeks. Clinical trials that led to Brainsway`s FDA clearance demonstrated excellent results using 33% less treatment sessions, with sessions which are almost 50% shorter than other forms of TMS technology.
  • Moreover, Deep TMS has no systemic side effects3-5,6.It is also highly convenient, as it can be administered in clinics of any size.
  • CLINICALLY PROVEN SAFE AND SAFE
  • The FDA7 and the CE have approved Brainsway Deep TMS for treatment of a wide range of patients, suffering from mild to severe and persistent depression, who did not improve following the use of any number of antidepressants (in the current depressive episode).
  • The FDA indication is based on a unique long-term 16-week double-blind placebo-controlled multi-center study which enrolled over 230 subjects, showing a profound decline in HDRS-21 and significant remission (32.6%) and response (38.4%) rates at the primary endpoint of the study. In the study, Brainsway`s treatment was proven to be safe, and the treatment was well tolerated by the majority of the study subjects.